With the aim to translate the discovery from proteomic research into clinical applications, we identified epidermal fatty acid-binding protein (E-FABP) and calcyphosine (CAPS) by MALDI-QTOF MS and validated their overexpressions by immunoblotting. Their expression statuses were examined by immunohistochemistry in 39 normal endometrium, 29 endometrial intraepithelial neoplasia (EIN) and 84 endometrial cancer (EC) cases. We evaluated the correlations to the clinicopathologic characteristics and determined whether these proteins had prognostic significance. Expressions of E-FABP and CAPS were increased 2.64- and 2.18-fold in EC by immunoblotting. Immunoreactivity of both E-FABP and CAPS were stronger in EC than in EIN or normal tissues (p<0.001 and <0.001). Stronger mmunoreactivity of E-FABP and CAPS were shown to present with poor differentiation (p5 0.032 and 0.001), but no elevance was observed with staging (p 5 1.368and 4.306). Survival analysis indicated that mmunoreactivity of　CAPS was correlated to poor survival (p 5 0.018), but E-FABP　status appeared to be no correlation to the clinical outcome of　patients (p 5 0.865). Multivariate analysis indicated that CAPS　might be an independent prognostic factor for survival in patients　with EC (p 5 0.008). Results demonstrated the ubiquitous overexpressions　of E-FABP and CAPS in EC and the correlations to the　clinicopathologic parameters. CAPS might be a potential prognostic　factor for survival in patients with EC. The research pattern　from proteomics to clinical specimens would have widespread applications.